Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 173.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (44.0%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -0.5% (LTM)
  • Share price is 247.0% higher than minimum and 2.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (40.2x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $78 128.0 mln (-0.273% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (0.0%)1077.75
year average price 832.28  


year start price 787.22 2025-01-08

min close price 625.65 2025-08-08

max close price 1109.94 2025-11-25

current price 1077.75 2026-01-07
Common stocks: 900 605 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.5%
EV / LTM EBITDA: 40.2x
EV / EBITDA annualized: 32.0x
Last revenue growth (y/y):  +53.9%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +28.1%
Historical growth of EBITDA:  +59.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 970 627
Net Debt ($m): 32 651
EV (Enterprise Value): 1 003 278
EBITDA LTM ($m): 24 974
EV / LTM EBITDA: 40.2x
Price to Book: 40.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-01fool.com

Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.

2025-12-29fool.com

The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.

2025-12-28247wallst.com

Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026

2025-12-26marketbeat.com

Eli Lilly's New Drug Data Sets Up a High-Stakes 2026

2025-12-26fool.com

Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree

2025-12-23reuters.com

Focus: Lilly, Novo lock horns in India's obesity drug race

2025-12-23barrons.com

Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

2025-12-19benzinga.com

Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026

2025-12-17reuters.com

Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports

2025-12-17marketwatch.com

Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data